Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC

from TheBrief.Health · host TheBrief.Health

A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.

Episode metadata supplied by the publisher feed · Published Jun 22, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC

0:00 1:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on June 22, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!